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Abstract
Background: Gastric cancer (GC) surveillance based on oesophagogastroduodenoscopy (OGD) appears to be a promising
strategy for GC prevention. By evaluating the cost-effectiveness of endoscopic surveillance in Singaporean Chinese, this
study aimed to inform the implementation of such a program in a population with a low to intermediate GC risk.
Methods: Using a reference strategy of no OGD intervention, we evaluated four strategies: 2-yearly OGD surveillance,
annual OGD surveillance, 2-yearly OGD screening and 2-yearly screening plus annual surveillance in Singaporean Chinese
aged 50-69 years. From a perspective of the healthcare system, Markov models were built to simulate the life experience of
the target population. The models projected discounted lifetime costs ($), quality adjusted life year (QALY), and incremental
cost-effectiveness ratio (ICER) indicating the cost-effectiveness of each strategy against a Singapore willingness-to-pay of
$46,200/QALY. Deterministic and probabilistic sensitivity analyses were used to identify the influential variables and their
associated thresholds, and to quantify the influence of parameter uncertainties respectively.
Results:With an ICER of $44,098/QALY, the annual OGD surveillance was the optimal strategy while the 2-yearly surveillance
was the most cost-effective strategy (ICER = $25,949/QALY). The screening-based strategies were either extendedly
dominated or cost-ineffective. The cost-effectiveness heterogeneity of the four strategies was observed across age-gender
subgroups. Eight influential parameters were identified each with their specific thresholds to define the choice of optimal
strategy. Accounting for the model uncertainties, the probability that the annual surveillance is the optimal strategy in
Singapore was 44.5%.
Conclusion: Endoscopic surveillance is potentially cost-effective in the prevention of GC for populations at low to
intermediate risk. Regarding program implementation, a detailed analysis of influential factors and their associated
thresholds is necessary. Multiple strategies should be considered in order to recommend the right strategy for the right
population.
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Introduction
Mass screening for gastric cancer (GC) has been shown to
produce significant improvements in the survival of GC patients
[1–3]. However, it is still hard to justify the establishment of
population-based screening in a country with low to intermediate
GC risk because of concerns about cost-effectiveness. Hence, cost-
effectiveness evaluations of population-based GC screening are
currently limited to jurisdictions with the highest GC incidences in
the world, such as Japan, South Korea and Taiwan [4–6]. Due to
the dramatic impact on cost-effectiveness caused by different levels
of GC risk, the findings from these economic evaluations may not
be generalizable to other populations.
Endoscopic surveillance, whereby patients with precancerous
lesions are closely followed up for GC development by scheduled
oesophagogastroduodenoscopy (OGD) examinations, has previ-
ously demonstrated the ability to detect GC at an earlier curable
stage [7]. Multiple studies have provided evidence of the clinical
benefit and cost-effectiveness of endoscopic surveillance in patients
with atrophic gastritis, intestinal metaplasia, gastric ulcer or
dysplasia [8–11]. Thus, the economic feasibility of OGD-based
surveillance as a national strategy for GC prevention in countries
at low to intermediate risk is worthy of further investigation.
In Singapore, the majority Chinese population is at an
intermediate risk of GC [12]. The interest in early detection to
improve the survival and quality of life of GC patients has
stimulated a series of endeavors. Based on decision-analytic
models, Dan et al. previously reported that 2-yearly OGD
screening is cost-effective in Singaporean Chinese men aged 50–
70 years [13]; while Xie et al. evaluated the primary prevention
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strategy of H.pylori screening and eradication in Singaporean
Chinese aged 40 years or older [14]. Additionally, an ongoing
hospital-based demonstration project, the Gastric Cancer Epide-
miology, Clinical and Genetics Program (GCEP) [15] was initiated
in Singapore in 2004 with the intention of providing empirical
evidence of the feasibility and cost-effectiveness of endoscopic
surveillance.
However, consensus has yet to be reached regarding the optimal
strategy for GC prevention in Singapore. Furthermore, none of
these aforementioned studies has provided evidence regarding
cost-effectiveness as yet. Hence, to address this crucial knowledge
gap to assist decision-makers and clinicians, we constructed
Markov models to evaluate the cost-effectiveness of OGD-based
surveillance and mass screening. Our main objectives were to: (1)
inform the choice of optimal strategy for GC prevention within the
context of the Singapore heath care system and (2) provide
suggestions for actual implementation of an OGD-based surveil-
lance program in a country at low to intermediate GC risk. Our
study demonstrated that endoscopic surveillance is cost-effective
and is potentially the optimal strategy for GC prevention in a
country with low to intermediate GC risk.
Methods and Materials
Target Population
The target population was defined as Singaporean Chinese aged
50–69 years based on epidemiologic evidence that this cohort
carries 90% of the GC disease burden in Singapore and has a
sharp increase in GC risk after the age of 50 years [12].
Strategies compared
An overview of the focused surveillance strategies compared in
our study are illustrated in Figure 1. A baseline OGD examination
was used to screen the entire target population for high risk
subjects, who were defined by the presence of precancerous lesions
in the stomach. The high risk group was then subjected to OGD
follow-up while subjects without precancerous lesions, the low risk
group, remained under usual care. Considering the different
progression rates of different premalignancies in the stomach, we
evaluated two follow-up frequencies: annual OGD surveillance
and 2-yearly OGD surveillance as per the European Society of
Gastrointestinal Endoscopy Guidelines for management of
precancerous conditions and lesions in the stomach [16].
The screening strategy evaluated in our study was to examine
the whole cohort of 50–69 year old Chinese every two years in
light of a previous cost-effectiveness analysis by Dan et al [13].
Furthermore we combined 2-yearly screening with annual
surveillance as the most intensive strategy to explore the maximum
potential of early detection. Finally, using no OGD intervention as
the reference strategy, we compared to it the four strategies,
namely, 2-yearly OGD surveillance, annual OGD surveillance, 2-
yearly OGD screening and 2-yearly OGD screening plus annual
OGD surveillance.
Major Assumptions
To ensure clinical validity of our study, the Markov model was
built on the following assumptions.
1) The effect of the four strategies is limited to down-staging due
to early detection and thus GC incidence is not affected [1,17].
2) For the 2-yearly screening and the 2-yearly surveillance
strategies that deliver OGD services every other year, the early
detection effect persists in the interval years without OGD
examination but is less effective. The early detection effect is
assumed to be 40% (2-yearly screening) and 60% (2-yearly
surveillance) of that conferred by annual OGD follow-up for these
interval years.
3) The probability that precancerous lesions could regress to a
healthy or less advanced state for high risk subjects is negligible
[18].
4) Full subject compliance with the OGD schedule and full
adherence to standardized treatment following a positive OGD
was assumed.
5) GC patients receive the same standardized treatment after
diagnosis and therefore undergo the same survival experience for
all five strategies.
Markov states and utility
Markov states were broadly defined as (a) death (from GC or
other causes) with a utility of 0, (b) the four clinical stages, namely
GC stage 1, GC stage 2, GC stage 3 and GC stage 4 with the
stage-specific utility estimated as EQ-5D scores derived from our
previous quality of life study [19], (c) an asymptomatic state
assigned with a utility of 1, which encompasses all the remaining
Markov states.
Model Construction and Patient Flow
We adopted a perspective of the health care system for the
purpose of making the study informative for program implemen-
tation. Individual Markov models were first built for the reference
Figure 1. Overview of the surveillance strategy.
doi:10.1371/journal.pone.0083959.g001
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strategy and the four strategies (Figure S1–S5). Each model
simulated the life experience of the target population following the
clinical pathways specified by the evaluated strategies. A decision
tree was used to compare these five Markov models to identify the
optimal strategy (Figure S6). Our model discounted both cost and
effectiveness at an annual rate of 3% [20].
In each Markov model, the simulation started with the target
population being asymptomatic, i.e. the cohort was free of GC but
was exposed to GC risk. As the Markov modeling progressed, the
cohort developed GC governed by population incidences [21]. In
a given Markov model, all the incident GC patients were
diagnosed with one of four clinical stages. The distribution of
GC stages was determined as per clinical pathway of each strategy.
Using different stage proportions in accordance with the
predefined OGD proposal, the down-stage effect from screening
and surveillance was incorporated into the respective Markov
models. The GC cohorts corresponding to the four clinical stages
were modeled separately until death. If a subject did not suffer GC
in a given cycle, he/she would remain asymptomatic at the start of
the next cycle and go through another cycle of the modeling
process. The Markov models ran year by year until a minimum of
99% of the target population died.
Data synthesis
A PubMed literature search was conducted using key terms
‘‘endoscopic surveillance’’, ‘‘precancerous lesions’’, ‘‘gastric/stom-
ach cancer screening’’, ‘‘cost-effectiveness analysis’’ and ‘‘econom-
ic evaluation’’. Each article was assessed in terms of validity,
reliability and transferability. As per the generally accepted
hierarchy of evidence, systematic reviews and meta-analyses were
given the highest priority, followed by randomized control trials,
prospective cohort studies and cross-sectional studies. Data from
Singapore and other Asia-based studies were used as far as
possible. Point estimates and their plausible ranges were presented
for each input variable (Table 1).
Epidemiological Data
The background mortality of the target population was
represented by the life-tables of the 2011 Singapore population
[21]. For the GC patient cohort, the probability of dying from
other causes was calculated following the approach used in the
Cost of Illness Handbook, United States Environmental Protection
Agency [22]. In the Markov trees for the reference strategy and
the 2-yearly screening strategy, annual transition rates to GC were
represented by population incidences specific to age and gender
[12]. In the Markov trees for the two surveillance strategies and
the screening plus surveillance strategy, the transition rates were
computed based on the population incidences, the odds ratio of
GC associated with the high risk cohort [23] and the prevalence of
precancerous lesions estimated from the GCEP [15] and a
community survey in Singapore [24]. The down-stage effect was
projected from studies in Korea and Japan [25–27]. The sensitivity
and specificity of OGD was integrated into the Markov models for
screening and surveillance [28].
Cost
We estimated the incremental costs incurred in the healthcare
sector covering cancer treatment, post-treatment follow-up and
operation of a prevention program (Table 1). For cancer
treatment, we cost medical services utilization specific to each of
the four clinical stages (Table S1) in light of the costing rules in the
Cost of Illness Handbook [29]. Hospital charges were obtained
from the National University Hospital, the not-for-profit tertiary
medical institution where the international algorithm for GC
treatment is followed [30]. The post-treatment follow-up costs
encompassed all expenditures for diagnostic and therapeutic
services after initial acute care. Program operational costs in our
model were comprised of two parts, the cost of OGD and biopsy
and the program cost for activities such as manpower, case
management, quality control, transportation and subjects’ salary
loss due to program participation [31]. The program cost was
represented by its proportion of total operating budget. Practically,
this proportion indicates the operating efficiency of an actual
program [32,33]. Costs were expressed as 2012 constant United
States dollars ($) at an annual average exchange rate of 1.25
Singapore dollars.
Statistical Analysis
Following WHO guidelines [34], the Singapore GDP of
$46,200 per capita for the year 2011 was determined as the
willingness-to-pay (WTP) threshold. A strategy associated with an
ICER less than $46,200/QALY is considered cost-effective in
Singapore for our study.
Markov models were constructed using TreeAge Pro 2009
(TreeAge Software, Inc., Williamstown M.A., USA). After
populating the Markov models, we conducted internal validation
against the input GC incidences and life-tables. The consistency of
projected GC incidence and all-cause mortality with the popula-
tion data were confirmed by the Mantel–Cox log-rank test for
goodness-of-fit. In simulating the lifetime experience of the target
population, Markov models used cohort analysis to calculate the
outcomes of expected lifetime cost, lifetime effectiveness and the
incremental cost-effectiveness ratio (ICER), which is defined as the
additional cost ($) of a specific strategy divided by its additional
clinical benefit (QALY) relative to the next least expensive
alternative. Based on the ICERs of each strategy, the decision
tree suggested the optimal strategy, which is the one with the
highest ICER below the Singapore threshold of $46,200/QALY.
One-way deterministic sensitivity analysis was applied to
identify the parameters with significant impact on the model.
For the clinical and epidemiological parameters, the range for the
sensitivity analysis was based on the upper and lower bounds of
biological plausibility as reported in the literature. As cost data
follow right-skewed distributions [35], base case estimates were
halved and doubled to determine the range [6]. We analyzed the
net health benefit (NHB) projected by the model to quantify the
impact of the input parameters and to identify the associated
thresholds for choosing the best strategy. We did not run sensitivity
analyses on GC incidence as its variation have been well
represented by specific values across age and gender subpopula-
tions.
We conducted probabilistic sensitivity analysis (PSA) to assess
the influence of uncertainty surrounding point estimates of input
parameters. According to the data informing the point estimates,
nine parameters qualified for the PSA, during which 1000 Monte
Carlo cycles were exercised on the nine distributions assigned to
these parameters (Table 2). The results were summarized in the
form of the Cost-Effectiveness Acceptability Frontier which
presented the optimal strategy and its associated probability after




Given the Singapore specific WTP of 46,200/QALY, the 2-
yearly OGD surveillance and the annual OGD surveillance were
both considered cost-effective for the target population. The
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former was the most cost-effective strategy with the lowest ICER
of $25,949/QALY while the latter was the optimal strategy as the
annual OGD surveillance was projected to create 0.05 more
QALYs and prevent 2,140 more GC deaths than the 2-yearly
surveillance strategy (Figure 2). The 2-yearly screening strategy
was extendedly dominated by the combination of the annual
surveillance strategy and the 2-yearly screening plus annual
surveillance strategies.
Heterogeneity across age and gender subgroups
The performances of the four prevention strategies were
different across age-gender subgroups. As in Table 3, each of
the age-gender subgroups had its own cost, effectiveness, ICER
and the optimal strategy. These variations demonstrated the
heterogeneity of the strategies when applied to different risk groups
categorized by known factors for GC development. However, the
general trend was clear that males featured by higher GC risk
[12,21] were associated with much lower ICERs than female
subgroups of the same age. Older age groups generated lower
ICERs than those younger age groups independent of their
gender. As in base-case analysis, the extended dominance
occurred for the 2-yearly screening strategy in all subgroups.
Sensitivity analysis
Our model was found to be sensitive to eight parameters that
were each able to cause a minimum of 0.2 QALY change within
their clinical ranges. The relationship between these influential
parameters and the NHBs predicted for each strategy is
Table 1. Input variables and sources.
Parameters Base case estimates and Range Reference
Epidemiologic data
Incidence* (1/100,000) GC incidences of Singaporean Chinese [12]
Background mortality* (%) 2011 Life Table of Singaporean Chinese [21]
Prevalence of premalignancy (%) 13.50 (6.5– 27) [15,24]
Odds ratio{ 6.0 (2.4–21.5) [23]
5-Year Survival (Stage 1:2:3:4) 90%:70%:40%:0% [36]
Stage distribution of GC cohort (Stage 1:2:3:4)
Detected by programs 85%:4%:8%:3% [36,37]
Detected in usual practice 7%:17%:33%:43% [25–27]
OGD test characteristics
Sensitivity 0.93 (0.44 –0.99) [28]
Specificity 1 (0.95 – 1)
Cost parameters ($)
Baseline OGD/Biopsy in surveillance 350 (175–750) [31]
OGD/Biopsy 340 (170–680) [21]
Diagnosis & Staging` 740 (660 – 820)
Diagnosis & Staging1 1155 (960–1440)
Treatment
Stage 1 17000 (8500 – 34000) Hospital Charge 2012
Stage 2 27200 (13600 – 54400)
Stage 3 38000 (19000 – 76000)
Stage 4 15500 (7800 – 31100)
Post-treatment GC follow-up 955 (900–1300)
Program cost I (%) 40 (20–80) [31,32,38]
Utilities
Stage 1 0.88 (0.60 – 1.00) [19]
Stage 2 0.86 (0.62–0.99)
Stage 3 0.77 (0.58 – 0.95)
Stage 4 0.68 (0.51 – 0.84)
Other parameters
Discount rate (%) 3 (0–5) [39]
Willingness to pay ($1000/QALY) 46.2 (15– 100) [34]
*data are age and gender-specific.
{Odds ratio for GC of high risk group versus low risk group.
`Diagnosis and staging cost for GC cases detected by prevention strategy.
1Diagnosis and staging cost for GC cases detected in usual care.
IProportion of total operational cost.
doi:10.1371/journal.pone.0083959.t001
Cost-Effectiveness of Gastric Cancer Surveillance
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e83959
summarized in Table 4. As anticipated a priori, the discount rate,
age of starting surveillance, cost of follow-up OGD and proportion
of program cost were negatively correlated to the NHBs. The odds
ratio for GC of the high risk group, prevalence of premalignant
lesions, utility of GC Stage 1 and early detection effect in the
interval years of the 2-yearly surveillance program had positive
relationships with the model NHBs.
These influential parameters also had a strong impact on the
choice of optimal strategy. They were identified with one or two
cut-off values defining specific ranges where the optimal strategy
differed (Table 4). The matrix of influential parameters and their
Table 2. Distributions assigned to parameters in the probabilistic sensitivity analysis.
Input variables Type of Distribution Mean (S.D)
Utility Score
Stage 1 Gamma* 0.88 (0.05)
Stage 2 Gamma* 0.86 (0.07)
Stage 3 Gamma* 0.77 (0.10)
Stage 4 Gamma* 0.68 (0.08)
Odds ratio{ LogNormal* 6.00 (2.46)
Prevalence of premalignant gastric lesions (%) Beta1 13.5 (6.75)
Stage distribution of GC cases(Stage 1:2:3:4)
Population with OGD follow-up Dirichlet 85%:4%:8%:3%
Population without OGD follow-up Dirichlet 7%:17%:33%:43%
Age of starting OGD Actual distribution
*Methods of moments; S.D: standard deviation.
{Odds ratio of GC in high risk group relative to low risk group.
doi:10.1371/journal.pone.0083959.t002
Figure 2. Cost effectiveness analysis of the five strategies at base-case analysis.
doi:10.1371/journal.pone.0083959.g002
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thresholds has great implications in designing and operating an
actual healthcare program. For example, for odds ratio which
reflects the GC risk associated with precancerous lesions of high
risk subjects [23], our model identified a threshold of 5.46. This
finding implies that a subpopulation with a GC risk of 5.46 times
that of a healthy person should undergo annual OGD surveillance,
whereas a subpopulation with a GC risk of between 2.4 and 5.46
favored alternate OGD surveillance. Follow-up OGD was the
essential clinical service offered by the preventive strategies.
Offering this service at a cost below $208 would make the most
intensive strategy, 2-yearly screening plus annual surveillance, the
optimal strategy. If this cost exceeds $356, the least intensive
strategy of 2-yearly surveillance would be the optimal strategy.
PSA in our study helped to identify the optimal strategy and its
associated probability given the officially defined WTPs. As shown
in the Cost Effectiveness Acceptability Frontier (Figure 3), the
Table 3. Heterogeneity of the four strategies by cost, utility and ICER across age and gender subgroups.
Target population (years) Male (years) Female (years)
50–54 55–59 60–64 65–69 50–54 55–59 60–64 65–69 50–54 55–59 60–64 65–69
No OGD Intervention Cost ($) 475 534 592 632 621 705 784 844 341 380 420 448
Utility (QALY) 20.49 18.62 16.58 14.43 19.57 17.64 15.54 13.37 21.35 19.53 17.52 15.36
Surveillance Cost ($) 1892 1879 1854 1804 2002 2015 2000 1968 1795 1764 1725 1664
(2-yearly OGD) Utility (QALY) 20.54 18.67 16.64 14.5 19.64 17.71 15.63 13.45 21.39 19.57 17.56 15.41
ICER ($/QALY) 28,962 24,417 20,856 18,141 21,445 18,809 15,013 12,948 40,367 34,796 30,024 25,928
Surveillance Cost ($) 2640 2554 2451 2321 2716 2655 2561 2449 2579 2477 2361 2219
(annual OGD) Utility (QALY) 20.55 18.69 16.66 14.51 19.66 17.73 15.65 13.48 21.4 19.58 17.57 15.42
ICER ($/QALY) 56,328 46,291 36,598 30,753 32,290 25,704 19,958 15,954 94,451 80,694 64,118 56,268
Screening Cost ($) 6311 5846 5328 4759 6225 5769 5263 4712 6407 5930 5401 4816
(2-yearly OGD)* Utility (QALY) 20.58 18.72 16.7 14.55 19.71 17.79 15.72 13.56 21.41 19.6 17.59 15.44
ICER ($/QALY) 114,823 87,827 70,367 60,150 67,000 48,633 40,358 31,338 218,920 177,622 145,464 125,612
Screening Cost ($) 8191 7671 7081 6413 8114 7621 7036 6406 8268 7744 7146 6485
(2-yearly OGD) +
Surveillance Utility (QALY) 20.61 18.76 16.74 14.59 19.75 17.85 15.79 13.64 21.43 19.62 17.63 15.49
(annual OGD) ICER ($/QALY) 58,829 49,167 37,419 42,124 47,158 36,578 25,541 20,470 129,238 65,964 44,925 33,085
The optimal strategy for each subgroup is highlighted in bold font.
doi:10.1371/journal.pone.0083959.t003
Table 4. Influential parameters and their thresholds for the choice of optimal strategy.
Input parameters Range Relationship with Thresholds and the corresponding optimal strategy
model NHBs
Discount rate (%) 3–5 negative 3–3.20 3.20–5
annual surveillance 2-yearly surveillance
Age (year) 50–69 negative 50–57 57–64 64–69
2-yearly surveillance annual surveillance screening + surveillance
Program cost Proportion (%) 20–80 negative 20–43 43–80
annual surveillance 2-yearly surveillance
Cost of follow-up OGD ($) 170–680 negative 170–208, 208–356 356–680
surveillance + screening annual surveillance 2-yearly surveillance
Utility of GC Stage 1 0.6–1 positive 0.6–0.85 0.85–1
2-yearly surveillance annual surveillance
Odds ratio of high risk subjects 2.4–21.5 positive 2.4–5.46 5.46–21.5
2-yearly surveillance annual surveillance
Prevalence of premalignancy (%) 6.8–40 positive 6.8–14.97 14.97–40
annual surveillance 2-yearly surveillance
Early detection for surveillance 40–90 positive 40–62 62–90
program during interval years (%) annual surveillance 2-yearly surveillance
doi:10.1371/journal.pone.0083959.t004
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choice of optimal strategy evolved with increasing WTP. At the
Singapore WTP of $46,200/QALY, the expected optimal strategy
was the annual surveillance, which was consistent with the base-
case analysis. However, the finding was not definite but with a
probability of 44.5% after accounting for the model uncertainty.
Below the threshold of $20,100/QALY as reported in previous
Asian studies [5,6], none of the evaluated strategies was preferred
over no OGD intervention. The 2-yearly OGD surveillance
strategy started to demonstrate its advantage over others between
$20,100/QALY and $39,200/QALY. For the most commonly
used WTP of $50,000/QALY in advanced countries [40,41],
annual surveillance remained the optimal strategy.
Discussion
To the best of our knowledge, a state-funded GC surveillance
program has never been officially established in any country of the
world. Singapore, with its advanced health care system and a small
population, is an ideal place for implementation of such a program
and may well be used as a model for other jurisdictions, such as
countries with low to intermediate GC risk. In recent years,
Singapore has systematically explored the feasibility of an OGD-
based surveillance program for GC. A series of studies have been
launched to address the practical issues such as the cost efficiency
of delivering GC surveillance [31], quality of life in GC patients
[19] and the long-term outcome of high risk subjects [15].
Synthesizing these recent findings, our study contributed cost-
effectiveness data to the area of GC surveillance. These studies
taken together are very helpful for the implementation of an
evidence-based surveillance program for GC in Singapore.
As suggested by the Asia-Pacific consensus guidelines, it is not
feasible to screen the general population in a country with low to
intermediate GC incidence and mortality [42]. For these
countries, surveillance focusing on high risk subjects has emerged
as a promising alternative. Excluding the majority of low risk
subjects who may not develop GC during their lifetime,
surveillance intuitively represents a strategy of resource-saving
with little compromise in health gain. Our model evaluated four
prevention strategies, in order of increasing resource utilization:
the 2-yearly surveillance, the annual surveillance, the 2-yearly
screening and the 2-yearly screening plus annual surveillance. The
two surveillance programs were cost-effective for our target
population of Singaporean Chinese aged 50-69 years old with
an intermediate GC risk, whereas the strategies based on universal
screening were either extendedly dominated or cost-ineffective.
Changing from annual surveillance to 2-yearly screening produced
the biggest incremental cost. Moreover, the lifetime number of
OGD examinations tripled from 4.4 to 13.5 per subject (Figure 2).
Therefore, population-based screening would most certainly cause
a strain on many health care systems, for example, the insufficient
supply of facilities and qualified endoscopists as occurred in Japan
[43]. Focused surveillance, however, tends to be structured as a
hospital-based service, which has shown to be practical and
efficient due to easy subject recruitment and participation [44].
Delivering endoscopic GC surveillance through a hospital-based
structure has been proven effective and cost-effective in multiple
populations [7,10].
Annual OGD surveillance overall was found to be the optimal
strategy. However, it may not be the one-for-all solution given the
uneven distribution of GC risk in the target population. Gastric
cancer incidence is known to be related to age and gender [12,21].
Therefore the heterogeneity of the four strategies in response to
age and gender is expected and consequently the choice of optimal
strategy is different. This heterogeneity is closely relevant to
resource allocation and priority setting from a perspective of
program implementation. In line with the economic principle that
lower ICERs indicate better return on investment, resources
should be prioritized to male subgroups and older subjects. In
particular, the 65-69 year old males with the lowest ICER should
be favorably considered (Table 3). This finding is consistent with a
previous model suggesting that the age of 65 years is the optimal
age to start OGD follow-up [13].
In a country with high GC risk, it appears an easy decision that
population-based screening is the best strategy in prevention of
GC. This issue becomes more complicated for countries with a
relatively lower GC burden. As our target population is at an
Figure 3. Cost Effectiveness Acceptability Frontier of the optimal strategies.
doi:10.1371/journal.pone.0083959.g003
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intermediate GC risk, we evaluated the four strategies including
both screening and surveillance and conducted a comprehensive
sensitivity analysis. The matrix of influential parameters and their
respective thresholds (Table 4) illustrated the conditions or
requirements for the individual strategies to be cost-effective
within the Singapore context. With such an informative matrix,
choosing the optimal strategy for a given health care system
becomes a matter of modifying influential factors and achieving
certain thresholds. In our study the cost of follow-up OGD was
found to be influential, which was consistent with the models by
Dan et al [13] and Gupta et al [45]. Its price of $340 was
negotiated between the GCEP and the National University
Hospital and was cheaper than the normal hospital rate [31].
Another influential factor is the proportion of program cost
indicating the operational efficiency of an actual program [33].
Our model projected that annual surveillance is the preferred
strategy conditional on an efficient control of program cost below
43% of the total operating budget. Otherwise, the 2-yearly
surveillance has to be chosen, which would then produce less
health life years than the annual surveillance strategy.
It remains controversial what gastric lesions are amenable to
continuing GC surveillance. Following Correa’s model of GC
genesis, atrophic gastritis, intestinal metaplasia and dysplasia are
commonly perceived as precancerous lesions and therefore have
been suggested for OGD follow-up [16]. However, limiting the
target gastric premalignancies to these intermediate steps of the
Correa’s model may not fully realize the preventive potential of
OGD surveillance. In fact, other subgroups have also been
suggested for OGD follow-up, for example, gastric ulcer [9], first-
line relatives of the GC patient [46], people with blood pepsinogen
levels below 3mg/ml [47] or with certain genetic polymorphisms
[48]. The issue underlying the controversy is what degree of GC
risk justifies continuing OGD follow-up. In our study, we believe
that any traits which predispose certain subgroups to additional
GC risk deserve further investigation. Therefore, our model used
odds ratio with a wide range of 2.4 to 21.5 to represent excessive
GC risk attributable to various predisposing factors. The sensitivity
analysis identified a threshold of 5.46, below which the 2-yearly
surveillance should be recommended, or the annual surveillance is
the optimal strategy in Singapore. This finding does not address
the issue of the appropriate lesions for OGD surveillance. It
reflects a fundamental principle of economic evaluation, which is
to recommend the right strategy to the right population based on
cost-effective ratios.
When building our models for the surveillance strategies, we did
not use progression rates from other studies. Instead, we used the
epidemiological profile of the target population and the odds ratio
of high risk subjects to generate progression rates of GC for low
and high risk subgroups. There are good reasons to do so. The
epidemiological profile refers to two components; the GC
incidence which is positively associated with the cost-effectiveness
of a preventive strategy, and background mortality which exerts a
negative influence due to competing diseases [49]. Incorporating
the epidemiological profile this way makes our models not only
Singapore-relevant, but also adaptable to other jurisdictions by
simply inputting the epidemiological profile of the local popula-
tion. Another reason is that most progression rates are estimated in
populations at high GC risk [50,51]. However, our model is
framed for a population with low to intermediate GC risk.
Therefore, transferring these rates into our model will over-
estimate the GC risk. A systematic review on economic evaluations
of endoscopic surveillance of precancerous lesions concluded that
conflicting results from these studies were caused by heterogeneity
in the progression rates assumed in their models [52].
Making a decision solely based on the expected cost-effective-
ness ratios is premature as the likelihood associated with these
ratios is also valuable for an informed decision [53]. At the
Singapore WTP of $46,200/QALY, the result that annual
surveillance is the optimal strategy is strengthened by the same
recommendation from the PSA. Additionally PSA estimated a
probability of 44.5% illustrating how confident we are in the above
decision after accounting for the model uncertainties. The
uncertainty is an inevitable element in decision-making.
A few strengths about this study are noted. Both utility and cost
data were obtained from our studies on the target population
thereby improving the internal validity of our model. Unlike other
economic evaluations [8–10], we used the epidemiological profile
and odds ratio to estimate the progression rate of high risk subjects
for the surveillance strategies, which has increased the generaliz-
ability of our model.
Nevertheless, the study does have some limitations. To mitigate
the lead-time bias and length-time bias in the models simulating
the preventive strategies, we assumed the same survival experience
of GC patients for all the five strategies. The Markov structures
were also adjusted to ensure consistent GC incidences in each
model. As a result, extra survival time due to these two types of
bias was alleviated. However we cannot completely rule out their
existence. The compliance rate with the OGD schedule was
assumed to be 100% which is unlikely in reality [54,55]. However,
it is less likely that the model validity would be affected. The
current study aims to provide a conceptual assessment of the cost-
effectiveness potential of the surveillance and screening strategies
for future program implementation. To this end, our model has
provided useful data to avoid conceptual deficit [56].
Conclusion
Endoscopic surveillance has the potential to be a cost-effective
strategy in prevention of GC for populations with low to
intermediate risk. It is necessary for policy-makers to evaluate
multiple strategies for the purpose of recommending the appro-
priate strategy to certain subgroups. In implementing an
endoscopic surveillance program, influential factors have to be
identified and evaluated to achieve cost-effectiveness in a given
health care system and target population.
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